Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 448-458

  Ahlskog, J Eric ^a   Muenter, Manfred D ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Dyskinesias; Levodopa; Motor fluctuations; Parkinson's disease; Wearing off

Indexed keywords

LEVODOPA; SELEGILINE; TOCOPHEROL;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE DURATION; DYSKINESIA; FREQUENCY ANALYSIS; HUMAN; LONG TERM CARE; MEDLINE; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCIENTIFIC LITERATURE;

ADULT; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; AUSTRALIA; CANADA; DRUG TOLERANCE; DYSKINESIA, DRUG-INDUCED; EUROPE; HUMANS; HYPOKINESIA; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; RISK; TIME FACTORS; UNITED STATES;

EID: 0035353725     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1090     Document Type: Article

References (84)

1. Bedard PJ, Blanchet PJ, Levesque D, et al. Pathophysiology of l-dopa-induced dyskinesias. Mov Disord 1999;14:4-8.
2. Rascol O. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disord 1999;14:19-32.
3. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease. Neurology 1998;50:S1-S57.
4. Block G, Liss C, Reines S, Irr J, Nibbelink D, The-CR-First-Study-Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Eur Neurol 1997;37: 23-27.
5. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA 2000;283:2008-2012.
6. Dupont E, Mikkelsen B, Jakobsen J. Mesulergine in early Parkinson's disease: a double blind controlled trial. J Neurol Neurosurg Psychiatry 1986;49:390-395.
7. Riopelle RJ, Gawel MJ, Libman I, et al. A double-blind study of bromocriptine and l-dopa in de novo Parkinson's disease. Eur Neurol 1988;28:11-14.
8. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998; 13:39-45.
9. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-540.
10. LeWitt PA, Oxenkrug GF, McIntyre IM, McCauley RM. Peripheral carbidopa affects striatal monoamine oxidase activity. Neurology 1985;35:1258-1259.
11. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 2000;284:1931-1938.
13. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488.
14. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
15. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991;41:168-173.
16. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-205.
17. Pantelatos A, Fornadi F. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology. Parkinson's disease from basic research to treatment, vol 60. New York: Raven Press; 1993: 690-697.
18. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998; 13:885-894.
19. Godwin-Austen RB, Tomlinson EB, Frears CC, Kok HW. Effects of L-dopa in Parkinson's disease. Lancet 1969;2:165-168.
20. Mones RJ, Elizan TS. A short-term evaluation of L-dopa therapy in 34 patients with parkinsonism. J Mount Sinai Hospital N Y 1969;36:503-515.
21. Godwin-Austen RB, Frears CC, Bergmann S, Parkes JD, Knill-Jones RP. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet 1970;2:383-385.
22. Rinne UK, Sonninen V, Sirtola T. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Zeitschrift fur Neurologie 1972;202:1-20.
23. Yahr MD. Abnormal involuntary movements induced by dopa: clinical aspects. In: Barbeau A, McDowell FH, eds. L-dopa and Parkinsonism. Philadelphia, PA: F.A. Davis; 1970:101-109.
24. Martin WE, Loewenson RB, Resch JA, Baker AB. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974;24:912-919.
25. Martin WE, Loewenson RB, Bilek MK, Resch JA, Baker AB. Long-term treatment of Parkinson's disease with levodopa. J Chron Dis 1974;27:77-93.
26. Rinne UK, Sonninen V, Siirtola T. L-dopa treatment in Parkinson's disease. Europ Neurol 1970;4:348-369.
27. Markham CH. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Therapeut 1971;12:340-343.
28. Wodak J, Gilligan BS, Veale JL, Dowty BJ. Review of 12 months' treatment with L-dopa in Parkinson's disease, with remarks on unusual side effects. Med J Australia 1972; 2:1277-1282.
29. Mars H, Libman I, Schwartz AM, Gillo-Joffroy L, Barbeau A. L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area. Can Psychiatric Assoc J 1972; 17:123-131.
30. Rinne UK, Birket-Smith E, Dupont E, et al. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: a controlled clinical trial. J Neurol 1975;211:1-9.
31. Yahr MD, Duvoisin RC, Hoehn MM, Schear MJ, Barrett RE. L-dopa (L-3,4-dihydroxyphenylanine)-its clinical effects in parkinsonism. Trans Am Neurol Assoc 1968;93:56-63.
32. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can Med Assoc J 1969;101:59-68.
33. Calne DB, Stern GM, Spiers AS, Laurence DR. L-dopa in idiopathic parkinsonism. Lancet 1969; 2:973-976.
34. Pakkenberg H, Birket-Smith E, Dupont E, et al. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta Neurologica Scandinavica 1976;53:376-385.
35. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21: 343-354.
36. Hofmann WW, Ryan RL. A controlled study of L-DOPA in Parkinson's disease. Cal Med 1970;112:9-14.
37. Mawdsley C. Treatment of Parkinsonism with Laevo-dopa. Brit Med J 1970;1:331-337.
38. McDowell F, Lee JE, Swift T, Sweet RD, Ogsbury JS, Kessler JT. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). Ann Int Med 1970; 72:29-35.
39. Reef HE, Joffe R, Milletz H. Treatment of severe parkinsonism with L-dopa. South African Med J 1971; 45:504-5047.
40. Parkes JD, Baxter RC, Curzon G, et al. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study. Lancet 1971;1:1083-1086.
41. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673.
42. McFarland HR. Levodopa therapy for Parkinson's disease. A first-year experience with outpatients in private practice. Missouri Med 1971;68:843-847.
43. Presthus J, Holmsen R. Appraisal of long-term levodopa treatment of parkinsonism with special reference to therapy limiting factors. Acta Neurologica Scandinavica 1974; 50:774-790.
44. Calaghan N, McIlroy M, M OC. An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used incombination in Parkinson's Disease. Irish J Med Sci 1974;143:79-85.
45. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Quart J Med 1980;49:283-293.
46. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson disease. Neurology 1981;31:125-131.
47. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
48. Bergmann KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term levodopa therapy. In: Yahr MD, Bergmann KJ, eds. Advances in neurology. Parkinson's disease, vol 45. New York: Raven Press; 1986:463-467.
49. Cotzias GC, Papavasiliou PS, Gellene R. L-dopa in parkinson's syndrome. N Engl J Med 1969;281:272.
50. Muenter MD. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology 1970;20:6-13.
51. Campbell JB. Long-term treatment of Parkinson's disease with levodopa. Neurology 1970;20:18-22.
52. Barbeau A, Gillo-Joffroy L, Mars H. Treatment of Parkinson's disease with levodopa and Ro 4-4602. Clin Pharmacol Therapeut 1971;12:353-359.
53. Reveno WS, Bauer RB, Rosenbaum H. L-dopa treatment of parkinsonism. Geriatrics 1971; 26:61-70.
54. Murphy SF. Treatment of Parkinsonism with laevodopa. Irish J Med Sci 1971; 140:99-107.
55. Langrall HM, Joseph C. Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome. Clin-Pharmacol Therapeut 1971;12:323-331.
56. Martin WE. Adverse reactions during treatment of Parkinson's disease with levodopa. JAMA 1971;216:1979-1983.
57. Lee JE, Sweet RD, McDowell FH. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Int Med 1971; 75:703-708.
58. Lees AJ, Stern GM. Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up. In: Fahn S, Calne DB, Shoulson I, eds. Advances in neurology. Experimental therapeutics of movement disorders, vol 37. New York: Raven Press; 1983:9-15.
59. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198.
60. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Int Med 1975;83:456-463.
61. Friedman A. Levodopa-induced dyskinesia: clinical observations. J Neurol 1985; 232:29-31.
62. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-98.
63. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
64. Hoehn MMM. Parkinsonism treated wilth levodopa: progression and mortality. J Neural Trans Suppl. 19 1983; 253-264.
65. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
66. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
67. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998;55:23-30.
68. Vajda FJ, Donnan GA, Bladin PF. Patterns of response to levodopa in Parkinson's disease. Clin Exp Neurol 1978;15:299-306.
69. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36:1528-1530.
70. van der Drift JH. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study. In: Yahr MD, Bergmann KJ, eds. Advances in neurology. Parkinson's disease, vol 45. New York: Raven Press; 1986:529-534.
71. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
72. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-339.
73. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41:622-629.
74. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
75. Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311: 1602-1607.
76. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurologica Scandinavica 1996;93:14-20.
77. Myllyla VV, Sotaniemi KA, Hakulinen P, Maki-Ikola O, Heinonen EH. Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurologica Scandinavica 1997;95:211-218.
78. Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Mov Disord 1999;14:605-611.
79. Koller WC, Hutton JT, Tolosa E, Capilldeo R, the Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD. A 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
80. Larsen JP, Boas J, Erdal JE, the Norweigian Danish Study Group. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. Eur J Neurol 1999;6:539-547.
81. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342:1484-1491.
82. McDowell FH, Papavasiliou P, Sweet R. Long-term study and the effect of human growth hormone in parkinsonian patients treated with levodopa. In: Poirier LJ, Sourkes TL, Bedard PJ, eds. Advances in neurology. The extrapyramidal system and its disorders, vol 24. New York: Raven Press; 1979:475-488.
83. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
84. Larsen JP, Boas J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Mov Disord 1997;12:175-182.